Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Clinical Research in Cardiology
Erschienen in: Clinical Research in Cardiology 3/2008

01.03.2008 | REVIEW

The case for statin therapy in chronic heart failure

verfasst von: Pim van der Harst, Michael Böhm, Wiek H. van Gilst, Dirk J. van Veldhuisen

Erschienen in: Clinical Research in Cardiology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Both primary and secondary prevention studies have provided a wealth of evidence that statin therapy effectively reduces cardiovascular events. However, this general statement on the efficacy and safety of statin treatment has not been validated in patients with chronic heart failure (CHF). Recently, numerous statin trials have reported analysis on CHF parameters and numerous CHF trials have performed analysis on baseline statin use. In this article, we will review the currently available evidence from a pathophysiological as well as clinical perspective, building a case for and against the use of statins in CHF. From a pathophysiological perspective, we will discuss the known association of cholesterol and mortality, the ubiquinone, and the endotoxin–lipoprotein hypothesis. From a clinical perspective, we will discuss the observational studies, subgroup analysis of large randomized controlled trials, prospective randomized trials in CHF patients, and the future perspectives of the large European statin studies focussing on the statin therapy in CHF.
Literatur
1.
Afilalo J, Majdan AA, Eisenberg MJ (2007) Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart 93:914–921PubMedCrossRef
2.
Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, Davos CH, Banasiak W, Zardini P, Haass M, Senges J, Coats AJ, Poole-Wilson PA, Pitt B (2006) Statin use and survival in patients with chronic heart failure—results from two observational studies with 5200 patients. Int J Cardiol 112:234–242PubMedCrossRef
3.
Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104:982–985PubMedCrossRef
4.
Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, Rajagopalan S, Pitt B (2006) Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47:338–341PubMedCrossRef
5.
Bohm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, Van Veldhuisen DJ (2005) Heart failure and statins—why do we need a clinical trial? Z Kardiol 94:223–230PubMedCrossRef
6.
Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ (2007) Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case–control study. Lancet 369:107–114PubMedCrossRef
7.
De Pinieux G (1996) Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 42:333–337PubMedCrossRef
8.
Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R (2007) N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49:311–319PubMedCrossRef
9.
Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113:1086–1092PubMedCrossRef
10.
Genser B, Marz W (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 95:393–404PubMedCrossRef
11.
Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH (2006) Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296:2105–2111PubMedCrossRef
12.
Groenewegen HC, van der Harst P, Roks AJ, Buikema H, Zijlstra F, van Gilst WH, de Smet BJ (2007) Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation. Int J Cardiol [Epub ahead of print]
13.
Hong YJ, Jeong MH, Hyun DW, Hur SH, Kim KB, Kim W, Lim SY, Lee SH, Hong SN, Kang DG, Yun KH, Kim KH, Lee YS, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, Kang JC (2005) Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 95:619–622PubMedCrossRef
14.
Hoppe UC (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Clin Res Cardiol 96:196–198PubMedCrossRef
15.
Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS (2004) Statins Inhibit {beta}-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 110:412–418PubMedCrossRef
16.
Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC (2004) Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43:1439–1444PubMedCrossRef
17.
Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J (2005) A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7:1059–1069PubMedCrossRef
18.
Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687–3692PubMedCrossRef
19.
Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A (2007) Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 13:1–7PubMedCrossRef
20.
Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, Drexler H (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111:2356–2363PubMedCrossRef
21.
Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G (2004) Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93:103–108PubMedCrossRef
22.
Marz W, Siekmeier R, Muller HM, Wieland H, Gross W, Olbrich HG (2000) Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther 5:275–279PubMedCrossRef
23.
May HT, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Campbell BA, Kfoury AG, Lyon JL, Kim H, Renlund DG (2006) Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol 98:653–658PubMedCrossRef
24.
Mortensen SA (2003) Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of “Q-symbio”—a multinational trial. Biofactors 18:79–89PubMed
25.
Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJS, Anker SD (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838–1842PubMedCrossRef
26.
Node K, Fujita M, Kitakaze M, Hori M, Liao JK (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108:839–843PubMedCrossRef
27.
Rauchhaus M, Coats AJS, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356:930–933PubMedCrossRef
28.
Ray JG, Gong Y, Sykora K, Tu JV (2005) Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165:62–67PubMedCrossRef
29.
Reibis R, Dovifat C, Dissmann R, Ehrlich B, Schulz S, Stolze K, Wegscheider K, Voller H (2006) Implementation of evidence-based therapy in patients with systolic heart failure from 1998–2000. Clin Res Cardiol 95:154–161PubMedCrossRef
30.
Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, Noda A, Izawa H, Nagata K, Murohara T, Yokota M (2006) Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 47:770–779PubMedCrossRef
31.
Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E (2006) Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47:2326–2331PubMedCrossRef
32.
Smetanina IN, Vaulin NA, Masenko VP, Gratsianskii NA (2006) Short term simvastatin use in patients with systolic heart failure of ischemic origin did not preclude elevation of n-terminal pro-brain natriuretic peptide level. Kardiologiia 46:12–16PubMed
33.
Smetanina IN, Vaulin NA, Masenko VP, Gratsianskii NA (2006) Short term simvastatin use in patients with heart failure of ischemic origin. Changes of blood lipids, markers of inflammation and left ventricular function. Kardiologiia 46:44–49PubMed
34.
Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47:332–337PubMedCrossRef
35.
Strey CH, Young JM, Molyneux SL, George PM, Florkowski CM, Scott RS, Frampton CM (2005) Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179:201–206PubMedCrossRef
36.
Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM (2000) Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 86:514–518PubMedCrossRef
37.
Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M, on behalf of the GISSI-HF investigators (2004) Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6:635–641PubMed
38.
Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, Trikas A, Pitsavos C, Stefanadis C (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91:27–31PubMedCrossRef
39.
Van der Harst P, Asselbergs FW, Buikema H, Voors AA, Van Veldhuisen DJ, van Gilst WH (2006) Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting. Am J Cardiol 98:751–753PubMedCrossRef
40.
Van der Harst P, Voors AA, van Gilst WH, Bohm M, Van Veldhuisen DJ (2006) Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 3:e333PubMedCrossRef
41.
Van der Harst P, Voors AA, van Gilst WH, Bohm M, Van Veldhuisen DJ (2006) Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 71:443–454PubMedCrossRef
42.
Van der Harst P, Voors AA, Volbeda M, Buikema H, Van Veldhuisen DJ, van Gilst WH (2006) Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol 97:1697–1701PubMedCrossRef
43.
Van der Harst P, Wagenaar LJ, Buikema H, Voors AA, Plokker HW, Morshuis WJ, Six AJ, Boonstra PW, Nickenig G, Wassmann S, Van Veldhuisen DJ, van Gilst WH (2005) Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin ii in stable coronary artery disease. Am J Cardiol 96:1361–1364PubMedCrossRef
44.
Van der Harst P, van der Steege G, De Boer RA, Voors AA, Hall AS, Mulder MJ, van Gilst WH, Van Veldhuisen DJ, MERIT-HF Study Group (2007) Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 49:1459–1464PubMedCrossRef
45.
Van der Horst I, Voors AA, Van Veldhuisen DJ (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol 96:193–195PubMedCrossRef
46.
Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, Van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2007) Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28:2018–2027PubMedCrossRef
47.
Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, Dyrbus K, Badzinski A, Mercik G, Zembala M, Wodniecki J, Rozek MM (2006) Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97:899–904PubMedCrossRef
Metadaten
Titel
The case for statin therapy in chronic heart failure
verfasst von
Pim van der Harst
Michael Böhm
Wiek H. van Gilst
Dirk J. van Veldhuisen
Publikationsdatum
01.03.2008
Erschienen in
Clinical Research in Cardiology / Ausgabe 3/2008
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-007-0610-0

Weitere Artikel der Ausgabe 3/2008

Clinical Research in Cardiology 3/2008 Zur Ausgabe

ORIGINAL PAPER

Combined cardiac surgical procedures in octogenarians: operative outcome

ORIGINAL PAPER

Replacement of valved right ventricular to pulmonary artery conduits: an observational study with focus on right ventricular geometry

ORIGINAL PAPER

Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment

ORIGINAL PAPER

Transcatheter recanalization of acutely occluded modified systemic to pulmonary artery shunts in infancy

ORIGINAL PAPER

Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany

CLINICAL CORRESPONDENCE

Percutaneous closure of a saphenous vein graft aneurysm being at risk for rupture

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen